Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD
This study is testing a type of talk therapy called Trauma-focused psychodynamic psychotherapy for people living with HIV (PLWH) who also have Post Traumatic Stress Disorder (PTSD). This therapy helps you explore how past traumatic events might be affecting your emotions and relationships. The study aims to see if this therapy is helpful and acceptable for PLWH with PTSD. To join, you must be between 18 and 65 years old, have a diagnosis of PTSD and HIV, and be on stable psychiatric medication for at least two months. The study will measure success by looking at changes in your PTSD symptoms over 12 weeks. The current recruitment status is unclear, and the study plans to enroll 20 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 20 participants.
- What's involved
- The primary endpoints are measured at Baseline, Week 6, and Week 12 (treatment termination).
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants are followed until Week 12, which is when treatment ends.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Barbara Milrod, MD · PRINCIPAL_INVESTIGATOR · Montefiore Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in PTSD Score based on the Clinician Administered PTSD Scale for DSM-5Baseline
Lower scores denote less severe PTSD symptoms; a decline of at least 30% from an individual's baseline CAPS score is defined as a treatment response on the CAPS; diagnostic remission will be defined as achieving response plus failing to meet for DSM-5 defined PTSD per the CAPS after treatment.
- Change in PTSD Score based on the Clinician Administered PTSD Scale for DSM-5Week 6
Lower scores denote less severe PTSD symptoms; a decline of at least 30% from an individual's baseline CAPS score is defined as a treatment response on the CAPS; diagnostic remission will be defined as achieving response plus failing to meet for DSM-5 defined PTSD per the CAPS after treatment.
- Change in PTSD Score based on the Clinician Administered PTSD Scale for DSM-5Week 12 (treatment termination)
Lower scores denote less severe PTSD symptoms; a decline of at least 30% from an individual's baseline CAPS score is defined as a treatment response on the CAPS; diagnostic remission will be defined as achieving response plus failing to meet for DSM-5 defined PTSD per the CAPS after treatment.
- Change in PTSD Score based on the Clinician Administered PTSD Scale for DSM-53-month post-treatment follow-up
Lower scores denote less severe PTSD symptoms; a decline of at least 30% from an individual's baseline CAPS score is defined as a treatment response on the CAPS; diagnostic remission will be defined as achieving response plus failing to meet for DSM-5 defined PTSD per the CAPS after treatment.